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Abstract
Background—Solid organ transplant recipients have heightened risk for diffuse large B-cell 
lymphoma (DLBCL). The role of donor-recipient HLA mismatch and recipient HLA type on 
DLBCL risk are not well established.
Methods—We examined 172,231 U.S. kidney, heart, pancreas, and lung recipients transplanted 
between 1987 and 2010, including 902 with DLBCL. Incidence rate ratios (IRRs) were calculated 
using Poisson regression for DLBCL risk in relation to HLA mismatch, types, and zygosity, 
adjusting for sex, age, race/ethnicity, year, organ, and transplant number.
Results—Compared to recipients who had two HLA-DR mismatches, those with zero or one 
mismatches had reduced DLBCL risk, (zero: IRR=0.76, 95%CI=0.61–0.95; one: IRR=0.83, 
95%CI=0.69–1.00). In stratified analyses, recipients matched at either HLA-A, -B, or -DR had a 
significantly reduced risk of late-onset (>2 years after transplantation), but not early-onset, 
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DLBCL, and there was a trend for decreasing risk with decreasing mismatch across all three loci 
(P=0.0003). Several individual recipient HLA-A, -B, -C, -DR, and –DQ antigens were also 
associated with DLBCL risk, including DR13 (IRR=0.74, 95%CI=0.57–0.93) and B38 (IRR=1.48, 
95%CI=1.10–1.93), confirming prior findings that these two antigens are associated with risk of 
infection-associated cancers.
Conclusions—In conclusion, variation in HLA is related to susceptibility to DLBCL, perhaps 
reflecting intensity of immunosuppression, control of Epstein-Barr virus infection among 
transplant recipients, or chronic immune stimulation.
Introduction
Non-Hodgkin lymphoma (NHL) is the most common de novo malignancy, apart from 
nonmelanoma skin cancer, in solid organ transplant recipients. Diffuse large B-cell 
lymphoma (DLBCL) is the most common NHL subtype in the post-transplant setting, 
comprising approximately 73% of specified NHL subtypes.1 On average, DLBCL risk is 12 
times higher in solid organ transplant recipients than in the general population, and risk is 
even higher in specific subgroups, including children and lung or pancreas recipients.2–5 
DLBCL is also the most common cause of cancer-related deaths.6,7
Multiple factors likely contribute to the etiology of DLBCL in transplant recipients. A large 
fraction of cases is attributed to Epstein–Barr virus (EBV), which in absence of host immune 
control, drives lymphocyte proliferation. However, the occurrence of DLBCL in long-term 
transplant survivors appears to be caused by factors in addition to EBV.2,8,9
Human leukocyte antigens (HLAs) display foreign antigens to the immune system, thereby 
playing a central role in the generation of adaptive immune responses. The genes for HLA 
class I (HLA-A, -B, and -C) and class II (HLA-DRB1, -DQB1, and -DPB1) are the most 
polymorphic of all genes in mammals.10 Distinguishing between self and nonself antigens is 
an essential task of HLA, which is critical in transplant immunity, and differences in HLA 
between donor and recipient can cause transplant rejection. In a landmark study published in 
1969, Patel and Terasaki showed that the presence of anti-donor HLA antibodies was a 
major determinant of immediate graft loss.11 Even in the modern era of effective 
immunosuppressive medication regimens, HLA matching of donors to recipients remains an 
important component for placing donor organs for kidney transplantation, and there is 
accumulating evidence that HLA matching is beneficial for allograft and patient survival 
among recipients of lung, liver, and heart transplants.12,13,14 Other long-term effects 
associated with HLA incompatibility among solid organ transplant recipients, such as risk 
for developing DLBCL, have been largely unexplored.
In the general population, genetic variation in HLA has been associated with susceptibility 
to numerous infections and immunological diseases, including cancers with infectious 
origins.15–18 Several previous genetic association studies targeting HLA, as well as genome-
wide association studies, identified variants in HLA genes that were significantly associated 
with NHL susceptibility in the general population, including polymorphisms in HLA-B, 
HLA-DRB1, HLA-DQB1, and carriership of the ancestral haplotype HLA 8.1 (HLA-A:01-
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B:08-DR:03-TNFG-308A).19–25 It has also been observed that people who are homozygous 
for all three HLA class I alleles have an increased risk of DLBCL.19
Serologically defined HLA antigens are characterized for the majority of recipients for organ 
matching and/or evaluating immune risk. Serological methods assess HLA cell surface 
expression and so differ from the methods used in the previously summarized studies of 
HLA and NHL, which delineate genetic sequences in HLA. Several prior studies have 
examined the associations between HLA variants and susceptibility to DLBCL among solid 
organ transplant recipients, but due to the small study populations, the findings were 
variable.26–28
Understanding the role of HLA may shed light on the development of lymphomas in solid 
organ transplant recipients. To comprehensively evaluate the association between donor-
recipient HLA mismatch, individual HLA recipient antigens, and post-transplant DLCBL 
risk, we examined data from the Transplant Cancer Match (TCM) Study, a U.S. study of 
solid organ transplant recipients with systematic registry-based ascertainment of cancer 
outcomes.
Materials and methods
Detailed methods for the TCM Study (http://transplantmatch.cancer.gov/) have been 
published.29 In summary, the TCM Study is a linkage of the U.S. Scientific Registry of 
Transplant Recipients (SRTR, 1987–2010) with 15 U.S. population-based state or 
metropolitan area cancer registries. The SRTR includes structured data on all U.S. solid 
organ transplants including recipient demographics, transplant characteristics, and HLA type 
for the organ donor and recipient. The cancer registries collect standardized information on 
patient demographic characteristics and detailed tumor characteristics for all state-mandated 
reportable cancer cases. Record linkages were conducted using a computer-based matching 
algorithm followed by clerical review for confirmation of potential matches, resulting in 
coverage of approximately 46.2% of the U.S. transplant population from 1987 to 2010. The 
TCM Study was approved by human subjects research review committees at the National 
Cancer Institute and at participating cancer registries, as required.
In this study, transplant recipients were eligible if they had follow-up time (as defined 
below) covered by a participating cancer registry. From a total of 230,170 transplants, liver 
transplants were excluded (23.0%) because nearly half had no HLA data. Additionally, we 
excluded 2.6% of recipients of organs other than liver who had no HLA data, and <0.1% 
who were HIV-infected.30 After exclusions, our analytic cohort included 172,231 
transplants. DLBCL diagnoses were assessed in the cancer registries using International 
Classification of Diseases for Oncology, 3rd Edition morphology codes 9678–9680 or 9684.
Transplant recipients were considered at risk of DLBCL beginning at transplantation or the 
start of cancer registry coverage (whichever came later). Follow-up ended at first occurrence 
of a DLBCL diagnosis, death, failure of a transplanted organ, subsequent transplant, loss to 
follow-up, or last date of cancer registry coverage. Individuals were not excluded on the 
basis of a history of cancer prior to transplantation, and were not censored if they were 
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diagnosed with a cancer (other than DLBCL) after transplantation. Recipients were 
considered at risk separately during successive transplant episodes. Hispanics were followed 
beginning in 1992 to correspond to the years for which general population cancer rates were 
available.
Mismatch for HLA-A, -B, and –DR was determined by the SRTR variable for mismatch 
according to the historic matching standard at the time of transplantation. For each locus, the 
mismatch variable was categorized as 0, 1, or 2 mismatches. The total number of 
mismatched loci across A, B, and DR loci (ranging from 0 to 6) was calculated by adding up 
the mismatches at each locus.
Data on individual alleles at recipient HLA class I loci (A, B, and C) and class II loci (DR 
and DQ) were also determined from the SRTR records. Recipient HLA antigens were 
categorized as present versus absent for each locus. Rare antigens (present in less than 500 
transplant records) were excluded from these analyses. Since each individual has two 
antigens, an antigen could be present once or twice in the same individual. We also classified 
recipients at each locus as homozygous (all recipients who had two of the same antigens) or 
heterozygous (all recipients who had different antigens). When only one antigen was 
identified for a given locus, the recipient was considered to be homozygous for the present 
antigen. If a recipient was missing both antigens at a locus, the record was dropped from the 
analysis of that locus only. HLA-A, -B, and –DR antigen data were missing for less than 1% 
of the cohort. HLA-C and –DQ antigen data were missing in a more substantial fraction of 
the study population (36.0% and 15.2% missing, respectively). HLA-DP was not examined 
because it was missing in 99.8% of the study population.
HLA antigen classifications have evolved over time as tissue typing has changed from 
serotyping to cellular typing to DNA-based genotyping. These testing developments have 
allowed for the detection of differences in antigens (“split” categories) that were previously 
undistinguishable (“broad” categories). Our study included 21 groups of antigens that were 
affected by broad categories splitting over time. We used information on the frequencies of 
the broads/splits in each group and the year at which the splits came into existence to 
determine whether antigens would be analyzed as distinct split categories or harmonized by 
combining the broads and splits into a single category. Details are presented in 
supplementary materials. Briefly, 11 of these antigen groups contained broad categories that 
were almost completely phased out of use by 1987 (initial year for this study), thus each 
split category was analyzed separately and the rarely used broad categories were excluded. 
For four antigen groups, due to rarity of one or more of the split categories, broads and splits 
were harmonized into a single category. For six antigen groups, there was a gradual phase-
out of the broad categories and phase-in of the split categories over the transplant years 
included in the study. For these groups, broad categories were excluded, and split categories 
were included for transplants occurring on or after the year at which roughly two-thirds 
(67%) of the phase-in of the split category had been achieved.
We compared DLBCL risk among transplant recipients to that of the general population by 
calculating a standardized incidence ratio (SIR = observed/expected count). Expected counts 
were obtained by applying general population DLBCL rates to the person-time at risk 
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among transplant recipients, stratified by sex, age, race/ethnicity, calendar year, and registry. 
We also used Poisson regression to obtain incidence rate ratios (IRRs) that compared the 
incidence of DLBCL in relation to categories of HLA mismatch, each HLA antigen (present 
versus absent), and HLA zygosity (homozygous versus heterozygous). IRRs were adjusted 
for sex, age at transplant, race/ethnicity, year of transplant, transplanted organ, and transplant 
number. The impact of time since transplant on the IRRs was also examined. “Early-onset” 
DLBCL was defined as DLBCL diagnosed within two years following transplantation, and 
“late-onset” DLBCL occurred after two years. A two-year threshold was chosen based on 
prior observations that the incidence curves for PTLD and DLBCL as a function of time 
since transplantation have a natural inflection point at around two years post-transplant.2,31 
As a sensitivity analysis, we also calculated IRRs restricting the cohort to kidney recipients, 
given that they comprised 77.3% of our analytic cohort. These kidney transplant-specific 
calculations were also adjusted for panel reactive antibody (PRA) score and donor type 
(deceased versus living) given the possible influence of these factors on immunosuppression 
and thus risk for DLBCL. Bonferroni adjustment of the HLA antigen IRRs was done to 
account for multiple comparisons. All analyses were performed using Proc Genmod in SAS 
9.2 (Cary, NC).
Results
Table 1 describes characteristics of the transplant recipient population. We examined 
172,231 transplants with 823,542 person-years of follow-up (median 3.8 years). The 
majority of the cohort (60.9%) was male. A small proportion (7.4%) was under the age of 20 
years at transplantation, 9.2% were age 65 and above, and the majority were between the 
ages of 35 and 64 (65.8%). The population was racially and ethnically diverse, with 41.5% 
of recipients being non-white. The majority (77.3%) was kidney recipients, and 9% had 
received a prior transplant. A total of 902 DLBCLs were diagnosed during follow-up after 
transplantation, corresponding to a 12-fold increased risk compared with the general 
population (SIR 12.05, 95%CI 11.27–12.86, Table 4).
In the analysis of HLA mismatch, DLBCL risk was not associated with mismatch at the 
HLA-A or -B loci, alone (Table 2). However, DLBCL risk decreased with decreasing 
number of DR mismatches (P for trend=0.0149). Compared to recipients who were 
completely mismatched for HLA-DR (both antigens), DLBCL risk was lower among 
recipients with a single mismatch (IRR=0.83, P=0.0529) or no mismatches (IRR=0.76, 
P=0.0165). When all three loci were considered simultaneously, DLBCL risk appeared 
reduced among recipients with 0 to 5 mismatches (IRRs ranged from 0.67 to 0.84, compared 
to those who were completely mismatched at all three loci), although the trend was not 
statistically significant (P=0.0944). Very similar associations were observed for the kidney 
transplant subset (Supplementary Table 1).
When we examined early- and late-onset DLBCL separately, we observed substantial 
heterogeneity of the associations with HLA mismatch (Table 3). For early-onset DLBCL, 
risk was not associated with mismatch at HLA-B, or -DR, or combined A+B+DR. 
Decreasing number of mismatches at the HLA-A locus appeared to be associated with 
increasing risk of DLBCL, although the trend was marginal (P=0.0574). In contrast, for late-
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onset DLBCL, risk decreased with decreasing number of mismatches at HLA-A (P for trend 
= 0.0120), -B (P for trend=0.0148), -DR (P for trend = 0.0005), and A+B+DR (P for trend = 
0.0003). For HLA-DR specifically, late-onset DLBCL risk was decreased 42% among 
transplant recipients with no mismatches compared to those with two mismatches. For all 
loci combined, late-onset DLBCL risk was decreased 60% among transplant recipients with 
no mismatches compared to those who were completely mismatched over all three loci. 
Similar associations were observed for the kidney transplant subset, although late-onset 
DLBCL risk could not be assessed for DR and A+B+DR due to small numbers 
(Supplemental Table 2). Furthermore, similar associations were observed when a one year 
threshold was used to differentiate “early” versus “late” DLBCL (data not shown).
The associations between 88 antigen/antigen groups and DLBCL risk were examined 
(Supplementary Table 3). In Table 4, results are provided for all HLA antigen-DLBCL 
associations with a P value less than 0.10, ordered by ascending P values and grouped by 
locus. The Bonferroni-adjusted P value for 88 tests is 0.0006, and none of the antigen 
associations met this stringent significance criterion. Among the 14 antigens that had a P 
value < 0.05, 6 also had P value < 0.05 in the analyses restricted to kidney recipients 
(Supplementary Table 4). The most notable associations included B38 antigen, which was 
associated with a 1.48-fold increased risk of DLBCL with the lowest P value (P=0.0061, 
Table 4). Expression of the C12 antigen was associated with the largest departure from the 
null association with DLBCL (IRR=1.94, P=0.0337). Also, the B58 antigen was associated 
with a strong reduced DLBCL risk (IRR=0.47), with the second lowest P value (P=0.0071). 
The DR13 antigen, which was the strongest candidate antigen in this study based on prior 
studies,17,18,21,32,33 was associated with a reduced DLBCL risk (IRR=0.74, P=0.0144).
Finally, DLBCL risk was not associated with zygosity at any HLA locus (Table 5). 
Stratification of the HLA antigen or zygosity associations by early versus late-onset DLBCL 
did not reveal notable differences in IRRs (data not shown).
Discussion
To our knowledge, this is the first large-scale, population-based study of HLA and DLBCL 
risk following solid organ transplantation. We observed that transplant recipients who were 
matched to their donors for HLA-DR, had a 24% significantly decreased risk of DLBCL 
compared to mismatched recipients, which may reflect less intensive immunosuppression or 
lower levels of antigenic stimulation with better matching. Furthermore, we observed 
heterogeneity in the association between HLA mismatch and DLBCL risk by time since 
transplantation: a higher degree of matching at HLA-A, -B, -DR, and A+B+DR was 
significantly associated with a lower risk of late-onset DLBCL, but not early-onset DLBCL, 
consistent with differences in etiology. Additionally, we observed associations for a number 
of specific recipient HLA antigens in HLA-A, -B, -C, -DR, and –DQ with DLBCL risk, 
suggesting the importance of host-specific immune responsiveness to DLBCL-related 
antigens.
Results from studies evaluating the association between HLA mismatch and post-transplant 
outcomes related to lymphoid malignancies have been inconsistent. Most studies with 
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adequate sample sizes have been based in kidney transplant registries. In Australia and New 
Zealand, HLA mismatch was not associated with post-transplant lymphoproliferative 
disorder (PTLD, a spectrum of lymphoid cell proliferations including DLBCL) in about 
16,000 kidney transplant recipients.34 On the other hand, two larger studies from the U.S. 
and France reported that HLA mismatch overall was associated with increased PTLD risk, 
but did not examine associations with individual HLA loci.35,36 In a still larger study, 
including about 153,000 kidney transplant recipients, HLA-DR and HLA-B mismatches 
were associated with increased NHL risk.37 The association with HLA-DR mismatch was 
strikingly more pronounced for NHLs occurring in the kidney,37 and higher HLA-DR 
mismatch was associated with increased immunsuppression, including requirement for 
rejection treatment during the first year, use of T-cell–depleting antibodies for rejection 
treatment, and high dose of maintenance medications for up to 3 years.37 PTLD and NHL 
are heterogeneous entities, and some of the differences among prior studies and our results 
may reflect differences in the outcomes that were assessed or the substantially larger size of 
our study.
Our finding that HLA mismatch was most important as a risk factor for late onset DLBCL is 
open to several interpretations. One possibility is that mismatch leads to increased immune 
reactivity which necessitates intensified immunosuppressive treatment, resulting in 
decreased ability for the immune system to control EBV-infected B cells and EBV-driven 
lymphomagenesis. Our observation that HLA matching is protective for late, but not early, 
DLBCL, may be explained by the fact that intense immunosuppression is experienced by all 
transplant recipients in the first few years and tapers in the later years. Thus the differences 
in immunosuppression related to HLA mismatch may only become apparent in the later 
years.. Interestingly, in prior research based in the TCM Study, HLA mismatch has not been 
a significant factor in determining risk for other infection-related cancers, including human 
papillomavirus associated cancers,32 Burkitt lymphoma,38 plasma cell neoplasms,39 or 
Kaposi’s sarcoma,40 suggesting that HLA mismatch may be more than a marker for immune 
suppression in this study of DLBCL. Another possibility is that mismatch causes chronic 
antigenic stimulation by the allograft, contributing to chronic B-cell activation, thereby 
increasing the gradual acquisition of lymphomagenic molecular lesions. This notion is 
supported by data suggesting that EBV is less critical to the development of late DLBCLs.2
After correcting for multiple comparisons, no associations with specific HLA antigens 
remained statistically significant in our analyses. However, several associations that did not 
meet this stringent significance level are still worth discussing. The most remarkable was 
with HLA-B38, which was associated with a 1.48-fold increased risk of DLBCL 
(P=0.0061). In a small previous study, B38 was associated with a 4-fold increase in risk for 
EBV-positive PTLD (P=0.0004).41 B38, for which there are at least 16 allelic variants,42 is a 
“sister” split category of B39 (both from the broad category B16) which we did not find to 
be associated with DLBCL (IRR=0.85, P=0.3392). The consistency of our finding with the 
prior report on PTLD argues against the possibility that this is a chance finding, particularly 
in light of the fact that HLA-B is the most diverse HLA locus, constituting more than half 
(nearly 2,000) of the distinct HLA class I molecules.30
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Among individual class II antigens, DR13 was associated with a notable 26% decreased risk 
of DLBCL (P=0.0144). DR13 has more than 50 allelic variants, many of which are 
extremely rare. Accumulating data suggest that DR13 has an important role in immunity to 
oncoviruses. In a previous study of human papillomavirus-associated cancers that also used 
data from the TCM Study, Madeleine et al. reported that the DR13 antigen was significantly 
associated with a reduced risk of cervical and vulvar cancers.32 Similar protective 
associations have been observed in immunocompetent populations between allelic variants 
DRB1*13:01 and DRB1*13:02 and cervical neoplasia.17,18 Additionally, among 
immunocompetent people, carriership of DRB1*13:01, *13:02, or *13:03 is associated with 
decreased risk of NHL, mainly for follicular lymphoma rather than DLBCL.21,33 Some of 
the associations that we observed between individual HLA antigens and DLBCL may reflect 
the complex relationship between EBV and HLA. EBV epitopes are targeted by EBV-
specific cytotoxic lymphocytes in an HLA-restricted manner.43,44 It is plausible that HLA 
type influences this interaction and thus the immune regulation of EBV. HLA variants may 
also affect the efficiency of immune surveillance for non-viral tumor antigens. Given the 
highly polymorphic nature of HLA, and strong linkage disequilibrium patterns across the 
region, it is also possible that these associations reflect contributions of other genes to the 
development of transplant-associated DLBCL.
We did not observe an association between HLA zygosity and DLBCL. Heterozygosity at 
HLA loci has been found to confer an advantage in immune control for infectious diseases, 
such as HIV, presumably due to the wider array of peptides that can be presented to T-
cells.45 However, in certain situations, homozygosity may actually be beneficial for immune 
control.46 Our findings are in contrast to a prior observation that allelic HLA homozygosity 
was associated with increased DLBCL risk among immunocompetent people.19
Because we relied on serologic assessment of HLA, we cannot rule out that we missed some 
true associations with genetically defined alleles or zygosity. DNA-based methods are 
becoming common practice in HLA typing laboratories. Nonetheless, serological typing 
methods have been standardized by the exchange of reagents and cells in the International 
Histocompatibility Workshops, and the serological equivalencies for genetic variants have 
been expertly assigned, allowing comparability with genetic data.42 HLA split categories, 
resulting from improving specificities of HLA serotyping methods over time, presented an 
analytic challenge. We erred on the side of maintaining split categories as distinct entities in 
our analyses due to the possibility that collapsing split categories to harmonize them with 
the broader categories could mask important differences. However, when the split categories 
were too rare to examine separately, we analyzed the splits and broads together as a single 
category, for example, combining A28 (broad), A68 (split), and A69 (split).
An important strength of this study is the examination of DLBCL in more than 170,000 
transplants, which allowed us to assess associations with relatively rare HLA antigens. 
Because we captured DLBCLs arising over an extended period, we were also able to 
examine associations in different intervals since transplantation. Furthermore, the TCM 
Study comprises a well-defined, population-based sample of the U.S. transplants, and 
linkage with cancer registries allowed for complete and uniform cancer ascertainment.
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A limitation of this study was the lack of data on long-term immunosuppressive 
medications. We therefore could not assess whether differences in intensity of 
immunosuppression mediated the observed associations between HLA mismatch and 
DLBCL risk. Furthermore, cancer registries do not collect information on tumor EBV status, 
so we could not stratify risks for EBV-positive and -negative DLBCL. Also, biogeographical 
ancestry is an important determinant of HLA, and may be associated with DLBCL risk. We 
adjusted our analyses for self-reported race, but it is possible that some residual confounding 
remains. Finally, since DLBCLs can arise very late in the post-transplant period, we are 
likely underestimating the incidence of DLBCLs in our study, particularly if recipients 
moved out of the cancer registry areas. However, out-migration is uncommon in this 
population,29 and we have no reason to believe that the length of follow-up would depend on 
HLA and cause bias in our results. We included 547,653 person-years of follow-up in the 
period >2 years post-transplant (twice as much follow-up time as compared to the period ≤2 
years), providing a sufficient population from which to estimate DLBCL risk by HLA status 
in both strata.
In conclusion, these findings suggest that specific subgroups of solid organ transplant 
recipients may be more susceptible to developing post-transplant DLBCL based on their 
HLA composition and degree of HLA mismatch with the organ donor. Future studies should 
aim to define the underlying mechanisms that are responsible for the observed HLA antigen 
associations. It will also be important to assess the relationship of HLA with control of EBV 
infection, relative intensity of immunosuppressive therapy, and chronic antigenic 
stimulation.
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Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
Funding: This research was supported in part by the Intramural Research Program of the National Cancer Institute. 
The authors gratefully acknowledge the support and assistance provided by individuals at the Health Resources and 
Services Administration (Monica Lin), the SRTR (Paul Newkirk), and the following cancer registries: the states of 
California, Colorado (Jack Finch), Connecticut (Lou Gonsalves), Georgia (Rana Bayakly), Hawaii (Brenda 
Hernandez), Iowa, Illinois (Lori Koch), Michigan (Glenn Copeland), New Jersey (Xiaoling Niu), New York (Amy 
Kahn), North Carolina (Chandrika Rao), Texas (Melanie Williams), and Utah (Janna Harrell), and the Seattle-Puget 
Sound area of Washington (Margaret Madeleine). We also thank analysts at Information Management Services for 
programming support (David Castenson, Matthew Chaloux, Michael Curry, Ruth Parsons).
The views expressed in this paper are those of the authors and should not be interpreted to reflect the views or 
policies of the National Cancer Institute, Health Resources and Services Administration, SRTR, cancer registries, or 
their contractors.
The SRTR is currently operated under contract number HHSH250201000018C (Health Resources and Services 
Administration) by the Minneapolis Medical Research Foundation, Minneapolis, MN. During the initial period 
when registry linkages were performed, the SRTR was managed by Arbor Research Collaborative for Health in 
Ann Arbor, MI (contract HHSH234200537009C). The following cancer registries were supported by the SEER 
Program of the National Cancer Institute: California (contracts HHSN261201000036C, HHSN261201000035C, 
and HHSN261201000034C), Connecticut (HHSN261201000024C), Hawaii (HHSN261201000037C, N01-
PC-35137, and N01-PC-35139), Iowa (HSN261201000032C and N01-PC-35143), New Jersey 
(HHSN261201300021I, N01-PC-2013-00021), Seattle-Puget Sound (N01-PC-35142), and Utah 
(HHSN2612013000171). The following cancer registries were supported by the National Program of Cancer 
Registries of the Centers for Disease Control and Prevention: California (agreement 1U58 DP000807-01), Colorado 
(U58 DP000848-04), Georgia (5U58DP003875-01), Illinois (5U58DP003883-03), Maryland (U58DP12-1205 
Hussain et al. Page 9













3919-03), Michigan (5U58DP003921-03), New Jersey (5U58/DP003931-02), New York (U58DP003879), North 
Carolina (U58DP000832) and Texas (5U58DP000824-04). Additional support was provided by the states of 
California, Colorado, Connecticut, Illinois, Iowa, Massachusetts (Massachusetts Cancer Prevention and Control 
Cooperative Agreement 5458DP003920), New Jersey, New York (including the Cancer Surveillance Initiative), 




DLBCL diffuse large B cell lymphoma
EBV Epstein–Barr virus
HLA human leukocyte antigens
IRR incidence rate ratios
NHL non-Hodgkin lymphoma
PRA panel reactive antibody
PTLD post-transplant lymphoproliferative disorder
SRTR Scientific Registry of Transplant Recipients
SIR standardized incidence ratio
TCM Transplant Cancer Match
References
1. Clarke CA, Morton LM, Lynch C, et al. Risk of lymphoma subtypes after solid organ transplantation 
in the United States. British Journal of Cancer. Jul; 2013 109(1):280–288. [PubMed: 23756857] 
2. Gibson TM, Engels EA, Clarke CA, Lynch CF, Weisenburger DD, Morton LM. Risk of diffuse large 
B-cell lymphoma after solid organ transplantation in the United States. Am J Hematol. 2014; 3(10):
23726.
3. Vegso G, Hajdu M, Sebestyen A. Lymphoproliferative Disorders After Solid Organ Transplantation-
Classification, Incidence, Risk Factors, Early Detection and Treatment Options. Pathology & 
Oncology Research. Sep; 2011 17(3):443–454. [PubMed: 21193979] 
4. Kauffman HM, Cherikh WS, McBride MA, Cheng YL, Hanto DW. Post-transplant de novo 
malignancies in renal transplant recipients: the past and present. Transplant International. Aug; 2006 
19(8):607–620. [PubMed: 16827677] 
5. Fernberg P, Edgren G, Adami J, et al. Time Trends in Risk and Risk Determinants of Non-Hodgkin 
Lymphoma in Solid Organ Transplant Recipients. American Journal of Transplantation. Nov; 2011 
11(11):2472–2482. [PubMed: 21883909] 
6. Farrugia D, Mahboob S, Cheshire J, et al. Malignancy-related mortality following kidney 
transplantation is common. Kidney International. Jun; 2014 85(6):1395–1403. [PubMed: 24257690] 
7. Na R, Grulich AE, Meagher NS, McCaughan GW, Keogh AM, Vajdic CM. De novo Cancer-Related 
Death in Australian Liver and Cardiothoracic Transplant Recipients. American Journal of 
Transplantation. May; 2013 13(5):1296–1304. [PubMed: 23464511] 
8. Morscio J, Dierickx D, Tousseyn T. Molecular Pathogenesis of B-Cell Posttransplant 
Lymphoproliferative Disorder: What Do We Know So Far? Clinical & Developmental Immunology. 
2013; :13. Article ID 150835. doi: 10.1155/2013/150835
Hussain et al. Page 10













9. Morscio J, Dierickx D, Ferreiro JF, et al. Gene expression profiling reveals clear differences between 
EBV-positive and EBV-negative posttransplant lymphoproliferative disorders. Am J Transplant. 
2013; 13(5):1305–1316. [PubMed: 23489474] 
10. Trowsdale J, Campbell RD. Complexity in the Major Histocompatibility Complex. Eur J 
Immunogenet. Feb-Apr;1992 19(1–2):45–55. [PubMed: 1567814] 
11. Patel R, Terasaki PI. Significance of Positive Crossmatch Test in Kidney Transplantation. New 
England Journal of Medicine. 1969; 280(14):735–&. 1969. [PubMed: 4886455] 
12. Peltz M, Edwards LB, Jessen ME, Torres F, Meyer DM. HLA mismatches influence lung 
transplant recipient survival, bronchiolitis obliterans and rejection: Implications for donor lung 
allocation. Journal of Heart and Lung Transplantation. Apr; 2011 30(4):426–434. [PubMed: 
21145259] 
13. Muro M, Lopez-Alvarez MR, Campillo JA, et al. Influence of human leukocyte antigen 
mismatching on rejection development and allograft survival in liver transplantation: Is the 
relevance of HLA-A locus matching being underestimated? Transplant Immunology. Mar; 2012 
26(2–3):88–93. [PubMed: 22129495] 
14. Ansari D, Bucin D, Nilsson J. Human leukocyte antigen matching in heart transplantation: 
systematic review and meta-analysis. Transpl Int. 2014; 27(8):793–804. [PubMed: 24725030] 
15. Dorak MT, Yee LJ, Tang JM, et al. HLA-B,-DRB1/3/4/5, and-DQB1 gene polymorphisms in 
human immunodeficiency virus-related Kaposi’s sarcoma. Journal of Medical Virology. Jul; 2005 
76(3):302–310. [PubMed: 15902698] 
16. Masala MV, Carcassi C, Cottoni F, Mulargia M, Contu L, Cerimele D. Classic Kaposi’s sarcoma in 
Sardinia: HLA positive and negative associations. International Journal of Dermatology. Sep; 2005 
44(9):743–745. [PubMed: 16135142] 
17. Madeleine MM, Johnson LG, Smith AG, et al. Comprehensive analysis of HLA-A, HLA-B, HLA-
C, HLA-DRB1, and HLA-DQB1 loci and squamous cell cervical cancer risk. Cancer Research. 
May; 2008 68(9):3532–3539. [PubMed: 18451182] 
18. Wang SS, Wheeler CM, Hildesheim A, et al. Human Leukocyte Antigen Class I and II Alleles and 
Risk of Cervical Neoplasia: Results from a Population-Based Study in Costa Rica. J Infect Dis. 
Nov 15; 2001 184(10):1310–1314. 2001. [PubMed: 11679920] 
19. Wang SS, Abdou AM, Morton LM, et al. Human leukocyte antigen class I and II alleles in non-
Hodgkin lymphoma etiology. Blood. 2010; 115(23):4820–4823. [PubMed: 20385791] 
20. Wang SS, Menashe I, Cerhan JR, et al. Variations in chromosomes 9 and 6p21.3 with risk of non-
Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev. 2011; 20(1):42–49. [PubMed: 
21148756] 
21. Smedby KE, Foo JN, Skibola CF, et al. GWAS of follicular lymphoma reveals allelic heterogeneity 
at 6p21.32 and suggests shared genetic susceptibility with diffuse large B-cell lymphoma. PLoS 
Genet. 2011; 7(4):21.
22. Wang SS, Lu Y, Rothman N, et al. Variation in effects of non-Hodgkin lymphoma risk factors 
according to the human leukocyte antigen (HLA)-DRB1*01:01 allele and ancestral haplotype 8.1. 
Plos One. 2011; 6(11):9.
23. Cerhan JR, Fredericksen ZS, Novak AJ, et al. A two-stage evaluation of genetic variation in 
immune and inflammation genes with risk of non-Hodgkin lymphoma identifies new susceptibility 
locus in 6p21.3 region. Cancer Epidemiol Biomarkers Prev. 2012; 21(10):1799–1806. [PubMed: 
22911334] 
24. Cerhan JR, Berndt SI, Vijai J, et al. Genome-wide association study identifies multiple 
susceptibility loci for diffuse large B cell lymphoma. Nat Genet. 2014; 46(11):1233–1238. 
[PubMed: 25261932] 
25. Bassig BA, Cerhan JR, Au WY, et al. Genetic susceptibility to diffuse large B-cell lymphoma in a 
pooled study of three Eastern Asian populations. Eur J Haematol. 2015; 22(10):12513.
26. Pourfarziani V, Einollahi B, Taheri S, Nemati E, Nafar M, Kalantar E. Associations of Human 
Leukocyte Antigen (HLA) haplotypes with risk of developing lymphoproliferative disorders after 
renal transplantation. Annals of Transplantation. Oct-Dec;2007 12(4):16–22. [PubMed: 18344933] 
Hussain et al. Page 11













27. Wheless SA, Gulley ML, Raab-Traub N, et al. Post-transplantation Lymphoproliferative Disease 
Epstein-Barr Virus DNA Levels, HLA-A3, and Survival. American Journal of Respiratory and 
Critical Care Medicine. Nov; 2008 178(10):1060–1065. [PubMed: 18755927] 
28. Subklewe M, Marquis R, Choquet S, et al. Association of human leukocyte antigen haplotypes 
with posttransplant lymphoproliferative disease after solid organ transplantation. Transplantation. 
2006; 82(8):1093–1100. [PubMed: 17060859] 
29. Engels EA, Pfeiffer RM, Fraumeni JF, et al. Spectrum of Cancer Risk Among US Solid Organ 
Transplant Recipients. Jama-Journal of the American Medical Association. Nov; 2011 306(17):
1891–1901.
30. Goulder PJR, Walker BD. HIV and HLA Class I: An Evolving Relationship. Immunity. Sep; 2012 
37(3):426–440. [PubMed: 22999948] 
31. Quinlan SC, Pfeiffer RM, Morton LM, Engels EA. Risk factors for early-onset and late-onset post-
transplant lymphoproliferative disorder in kidney recipients in the United States. American Journal 
of Hematology. Feb; 2011 86(2):206–209. [PubMed: 21264909] 
32. Madeleine MM, Finch JL, Lynch CF, Goodman MT, Engels EA. HPV-Related Cancers After Solid 
Organ Transplantation in the United States. American Journal of Transplantation. Dec; 2013 
13(12):3202–3209. [PubMed: 24119294] 
33. Wang SS, Abdou AM, Morton LM, et al. Human leukocyte antigen class I and II alleles in non-
Hodgkin lymphoma etiology. Blood. Jun; 2010 115(23):4820–4823. [PubMed: 20385791] 
34. Faull RJ, Hollett P, McDonald SP. Lymphoproliferative disease after renal transplantation in 
Australia and New Zealand. Transplantation. Jul 27; 2005 80(2):193–197. [PubMed: 16041263] 
35. Caillard S, Dharnidharka V, Agodoa L, Bohen E, Abbott K. Posttransplant lymphoproliferative 
disorders after renal transplantation in the United States in era of modern immunosuppression. 
Transplantation. Nov 15; 2005 80(9):1233–1243. [PubMed: 16314791] 
36. Caillard S, Lamy FX, Quelen C, et al. Epidemiology of Posttransplant Lymphoproliferative 
Disorders in Adult Kidney and Kidney Pancreas Recipients: Report of the French Registry and 
Analysis of Subgroups of Lymphomas. American Journal of Transplantation. Mar; 2012 12(3):
682–693. [PubMed: 22226336] 
37. Opelz G, Dohler B. Impact of HLA Mismatching on Incidence of Posttransplant Non-Hodgkin 
Lymphoma After Kidney Transplantation. Transplantation. Mar; 2010 89(5):567–572. [PubMed: 
20110857] 
38. Mbulaiteye SM, Clarke CA, Morton LM, et al. Burkitt lymphoma risk in US solid organ transplant 
recipients. American Journal of Hematology. Apr; 2013 88(4):245–250. [PubMed: 23386365] 
39. Engels EA, Clarke CA, Pfeiffer RM, et al. Plasma Cell Neoplasms in US Solid Organ Transplant 
Recipients. American Journal of Transplantation. Jun; 2013 13(6):1523–1532. [PubMed: 
23635036] 
40. Mbulaiteye SM, Engels EA. Kaposi’s sarcoma risk among transplant recipients in the United States 
(1993–2003). International Journal of Cancer. Dec; 2006 119(11):2685–2691. [PubMed: 
16929513] 
41. Reshef R, Luskin MR, Kamoun M, et al. Association of HLA Polymorphisms with Post-transplant 
Lymphoproliferative Disorder in Solid-Organ Transplant Recipients. American Journal of 
Transplantation. Apr; 2011 11(4):817–825. [PubMed: 21401872] 
42. Holdsworth R, Hurley CK, Marsh SG, et al. The HLA dictionary 2008: a summary of HLA-A, -B, 
-C, -DRB1/3/4/5, and -DQB1 alleles and their association with serologically defined HLA-A, -B, -
C, -DR, and -DQ antigens. Tissue Antigens. 2009; 73(2):95–170. [PubMed: 19140825] 
43. Rickinson AB, Moss DJ. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. 
Annual Review of Immunology. 1997; 15:405–431. 1997. 
44. Subklewe M, Chahroudi A, Bickharn K, et al. Presentation of Epstein-Barr virus latency antigens 
to CD8(+), interferon-gamma-secreting, T lymphocytes. European Journal of Immunology. Dec; 
1999 29(12):3995–4001. [PubMed: 10602009] 
45. Carrington M, Nelson GW, Martin MP, et al. HLA and HIV-1: Heterozygote advantage and B*35-
Cw*04 disadvantage. Science. Mar 12; 1999 283(5408):1748–1752. [PubMed: 10073943] 
Hussain et al. Page 12













46. Flores-Villanueva PO, Yunis EJ, Delgado JC, et al. Control of HIV-1 viremia and protection from 
AIDS are associated with HLA-Bw4 homozygosity. Proceedings of the National Academy of 
Sciences of the United States of America. Apr 24; 2001 98(9):5140–5145. [PubMed: 11309482] 
Hussain et al. Page 13

























Hussain et al. Page 14
Table 1
Characteristics of 172,231 solid organ transplant recipients, U.S. 1987–2010
N %
Sex
 Female 67,409 39.1
 Male 104,822 60.9
Age at transplant, years
 0–19 12,772 7.4
 20–34 30,266 17.6
 35–49 54,635 31.7
 50–64 58,732 34.1
 65+ 15,826 9.2
Race/ethnicity
 White, non-Hispanic 100,800 58.5
 Black, non-Hispanic 35,058 20.4
 Hispanic 26,916 15.6
 Asian/Pacific Islander 9,457 5.5
Year of transplant
 1987–1992 16,086 9.3
 1993–1998 44,372 25.8
 1999–2004 56,553 32.8
 2005–2010 55,220 32.1
Transplanted organ
 Kidney (deceased donor) 85,307 49.5
 Kidney (living donor) 47,924 27.8
 Heart 19,533 11.3
 Pancreas or kidney-pancreas 9,890 5.7
 Lung 8,494 4.9
 Other/multiple 1,083 0.6
Transplant number
 1 156,690 91.0
 2+ 15,541 9.0
Panel reactive antibody score
 Missing 30,912 –
 0 66,088 46.8
 1–79 64,937 46.0
 80+ 10,294 7.3
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